An unusual prostate-specific antigen decrease in an advanced castration-resistant prostate cancer patient with intracerebral hemorrhage subsequently treated with luteinizing hormone-releasing hormone antagonist.

Abstract

An unusual prostate-specific antigen (PSA) decrease in a Japanese patient with advanced castration-resistant prostate cancer (CRPC) treated with luteinizing hormone-releasing hormone (LH-RH) antagonist after cerebral bleeding was presented. There have been no previous reports that cerebral bleeding or trepanation/drainage of hematoma decreased PSA level, which would make this the first. The LH-RH antagonist may be only one reason for the PSA decrease. More cases need to be accumulated and and further investigation is needed to clarify if intracerebral bleeding or an LH-RH antagonist can decrease PSA in such advanced CRPC cases.